001     134641
005     20250129092426.0
024 7 _ |a 10.1007/s11307-013-0621-3
|2 doi
024 7 _ |a pmid:23456885
|2 pmid
024 7 _ |a 1536-1632
|2 ISSN
024 7 _ |a 1860-2002
|2 ISSN
024 7 _ |a WOS:000321972500013
|2 WOS
037 _ _ |a FZJ-2013-02758
041 _ _ |a ENG
082 _ _ |a 610
100 1 _ |a Kroll, Tina
|0 P:(DE-Juel1)131691
|b 0
|u fzj
|e Corresponding author
245 _ _ |a Suitability of [18F]Altanserin and PET to Determine 5-HT2A Receptor Availability in the Rat Brain: In Vivo and In Vitro Validation of Invasive and Non-Invasive Kinetic Models
260 _ _ |a Amsterdam [u.a.]
|c 2013
|b Elsevier Science
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1378707244_1314
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
500 _ _ |3 POF3_Assignment on 2016-02-29
520 _ _ |a PURPOSE: While the selective 5-hydroxytryptamine type 2a receptor (5-HT2AR) radiotracer [(18)F]altanserin is well established in humans, the present study evaluated its suitability for quantifying cerebral 5-HT2ARs with positron emission tomography (PET) in albino rats. PROCEDURES: Ten Sprague Dawley rats underwent 180 min PET scans with arterial blood sampling. Reference tissue methods were evaluated on the basis of invasive kinetic models with metabolite-corrected arterial input functions. In vivo 5-HT2AR quantification with PET was validated by in vitro autoradiographic saturation experiments in the same animals. RESULT: Overall brain uptake of [(18)F]altanserin was reliably quantified by invasive and non-invasive models with the cerebellum as reference region shown by linear correlation of outcome parameters. Unlike in humans, no lipophilic metabolites occurred so that brain activity derived solely from parent compound. PET data correlated very well with in vitro autoradiographic data of the same animals. CONCLUSION: [(18)F]Altanserin PET is a reliable tool for in vivo quantification of 5-HT2AR availability in albino rats. Models based on both blood input and reference tissue describe radiotracer kinetics adequately. Low cerebral tracer uptake might, however, cause restrictions in experimental usage.
536 _ _ |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)
|0 G:(DE-HGF)POF2-333
|c POF2-333
|x 0
|f POF II
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de, PubMed,
700 1 _ |a Elmenhorst, David
|0 P:(DE-Juel1)131679
|b 1
|u fzj
700 1 _ |a Matusch, Andreas
|0 P:(DE-Juel1)138474
|b 2
|u fzj
700 1 _ |a Wedekind, Franziska
|0 P:(DE-Juel1)131711
|b 3
|u fzj
700 1 _ |a Weißhaupt, Angela
|0 P:(DE-Juel1)131712
|b 4
700 1 _ |a Beer, Simone
|0 P:(DE-Juel1)133864
|b 5
|u fzj
700 1 _ |a Bauer, Andreas
|0 P:(DE-Juel1)131672
|b 6
|u fzj
773 _ _ |a 10.1007/s11307-013-0621-3
|p 456-467
|n 4
|0 PERI:(DE-600)2079211-6
|t Molecular imaging & biology
|v 15
|y 2013
|x 1860-2002
856 4 _ |u https://juser.fz-juelich.de/record/134641/files/FZJ-2013-02758.pdf
|z Published final document.
|y Restricted
909 C O |o oai:juser.fz-juelich.de:134641
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)131691
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)131679
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)138474
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131711
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)131712
910 1 _ |a Zentralinstitut für Elektronik
|0 I:(DE-Juel1)ZEA-2-20090406
|k ZEA-2
|b 5
|6 P:(DE-Juel1)133864
910 1 _ |a Molekulare Organisation des Gehirns
|0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|b 5
|6 P:(DE-Juel1)133864
910 1 _ |a Zentralinstitut für Elektronik
|0 I:(DE-Juel1)ZEA-2-20090406
|k ZEA-2
|b 5
|6 P:(DE-Juel1)133864
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)133864
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131672
913 2 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-579H
|2 G:(DE-HGF)POF3-500
|v Addenda
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|1 G:(DE-HGF)POF2-330
|0 G:(DE-HGF)POF2-333
|2 G:(DE-HGF)POF2-300
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
914 1 _ |y 2013
915 _ _ |a Peer review unknown
|0 StatID:(DE-HGF)0040
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
920 1 _ |0 I:(DE-Juel1)ZEA-2-20090406
|k ZEA-2
|l Zentralinstitut für Elektronik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a I:(DE-Juel1)ZEA-2-20090406
981 _ _ |a I:(DE-Juel1)PGI-4-20110106
981 _ _ |a I:(DE-Juel1)ZEA-2-20090406


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21